COVID-19: Drugs in Development


The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Current Stage
Next Milestone
Last Updated
Phase 1 study of DYAI-100 was initiated- reported on Jan.24, 2023.

South African Health Products Regulatory Authority gave clearance to initiate Phase 1 study of DYAI-100 COVID-19 booster vaccine- reported on Oct. 27, 2022.

DYAI-100 advancing towards first-in-human Phase 1 clinical trial
Tevogen Bio
TVGN-489- to treat Covid-19
Positive results from the Proof-of-Concept (POC) study of TVGN 489 for the treatment of acute high-risk COVID-19 patients were reported on Jan.23, 2023.
Ascletis Pharma Inc.
Initiated Phase 1 study of ASC11 in combination with ritonavir, for the treatment of COVID-19- reported on Jan 15, 2023.
BiondVax Pharmaceuticals Ltd.
Inhaled COVID-19 NanoAb therapy
Lung viral titer was 30-times lower in hamsters infected with SARS-COV-2, that are treated with inhaled anti-COVID-19 nanosized antibodies (NanoAbs)- reported on Jan.6, 2023.

Statistically significant efficacy results from the pre-clinical study of inhaled nanosized antibody (NanoAb) COVID-19 therapy were reported on Nov.29, 2022.
First-in-human Phase 1/2a clinical trial planned in 2023
Valneva SE
Data showed that additional booster dose of VLA2001 in participants who were previously vaccinated with 2 or 3 doses of mRNA COVID-19 vaccine elicited only a marginally increased neutralizing antibody response- reported on Dec.30, 2022.

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
Drug major Pfizer Inc. reported Tuesday higher earnings in its fourth quarter, above market estimates, and an all-time high revenues in its fiscal 2022. Meanwhile, the company projects sharply lower adjusted earnings and revenues in its fiscal 2023, below Wall Street estimates, reflecting projected decline for COVID-19 products. In pre-market activity on the NYSE, Pfizer shares were losing around Oil major Exxon Mobil Corp. (XOM) reported Tuesday that fourth-quarter net income was $12.75 billion or $3.09 per share, up from $8.87 million or $2.08 per share in the prior-year quarter. Excluding special items, adjusted earnings were $3.40 per share, compared to $2.05 per share in the prior-year... La Mirada, California-based Daiso California LLC is recalling certain Matsunaga Mini Shiruko Sand Biscuits citing undeclared soy, an allergen, the U.S. Food and Drug Administration said. The recall incolves Matsunaga Mini Shiruko Sand Biscuits with sku 4902773016966, packaged in four pink and cream bags chained together. Each individual serving is 25g for an entire product weight of 100g.